Biosimilars Market by Product, Indication and Region – Global Forecast to 2026 – PRNewswire

DUBLIN, Nov. 10, 2021 /PRNewswire/ -- The "Global Biosimilars Market by Product (Monoclonal antibodies (infliximab, rituximab, trastuzumab), Insulin, Interferon, Etanercept, Glucagon, Calcitonin), Indication (Oncology, Chronic Disease, Blood Disorder, Autoimmune Disease), Region - Forecast to 2026" report has been added to ResearchAndMarkets.com's offering.

The global biosimilars market is projected to reach USD 44.7 billion by 2026 from USD 15.6 billion in 2021, at a CAGR of 23.5% during the forecast period of 2021 to 2026.

Market growth is largely driven by the rising incidence of chronic diseases and increasing demand of biosimilars for their cost-effectiveness. Regulatory approvals and other regulations favouring biosimilars adoption in different countries is also a major driving factor in the biosimilars market. However, the complexities in the development and manufacturing of biosimilars and resistance from reference biologic manufacturers is expected to restrain the growth of this market during the forecast period.

The monoclonal antibodies product segment accounted for the highest growth rate in the biosimilars market, by product, during the forecast period

In 2020, the monoclonal antibodies product segment accounted for the largest share (27.5%) of the biosimilars market, mainly due to the low prices of biosimilar monoclonal antibodies compared to the reference drugs and their wide use in the treatment of cancer, autoimmune disorders, and osteoporosis. They are also used in indications such as rheumatoid arthritis, multiple sclerosis, and macular degeneration. The growth of the fastest-growing segment was attributed to the rising incidence of cancer cases and chronic diseases and growth in the geriatric population.

Oncology segment accounted for the largest share of the indication segment

Based on the indication, the biosimilars market is segmented into oncology, inflammatory and autoimmune diseases, chronic diseases, blood disorders, growth hormone deficiency, infectious diseases, and other indications (infertility, hypoglycemia, myocardial infarction, postmenopausal osteoporosis, chronic kidney failure, and ophthalmic diseases). Oncology is the largest segment in this market owing to the availability of biosimilars at a lower price than innovative biologics and a large number of cancer patients.

The availability of biosimilars in the field of oncology has lowered prices and made cancer treatment more affordable and accessible. Also, due to the high incidence and prevalence of cancer, healthcare systems across the globe are focusing on reducing the burden of cancer by adopting cost effective treatment options. In this scenario, biosimilar drugs might witness widespread adoption in major markets such as the US, Europe, and the Asia Pacific. Considering these factors and the upending competition from biosimilars, many major biologic pharmaceutical companies are making significant investments in the development and approval of biosimilar drugs.

Asia Pacific: The fastest-growing region in the biosimilars market

The biosimilars market is segmented into Europe, Asia Pacific, North America, Latin America and Middle East and Africa. The APAC market, on the other hand, is expected to be the fastest-growing regional segment during the forecast period due to the presence of many emerging players, less-stringent regulations, and increasing cooperation among leading and regional players for development, manufacture and commercialization of biosimilars.

Key Topics Covered:

1 Introduction

2 Research Methodology

3 Executive Summary

4 Premium Insights4.1 Biosimilars Market Overview4.2 North America: Biosimilars Market, by Product and Country (2020)4.3 Geographical Snapshot of the Biosimilars Market

5 Market Overview5.1 Introduction5.2 Market Dynamics5.2.1 Drivers5.2.1.1 Increasing Demand for Biosimilar Drugs due to Their Cost-Effectiveness5.2.1.2 Rising Geriatric Population and the Increasing Incidence of Chronic Diseases5.2.1.3 Abbreviated Regulatory Approval Process and Concept of Interchangeability5.2.2 Restraints5.2.2.1 Complexities in Manufacturing5.2.2.2 Resistance from Biologics Manufacturers5.2.3 Opportunities5.2.3.1 Emerging Markets5.2.3.2 Patent Expiry of Blockbuster Biologics and Research on New Indications5.2.4 Challenges5.2.4.1 Excess Competition5.2.5 Trends5.2.5.1 Collaborations for Biosimilar Research and Clinical Trials5.3 COVID-19 Impact Analysis5.4 Technology Analysis5.5 Value Chain Analysis5.6 Ecosystem Market Map5.7 Supply Chain Analysis5.8 Porter's Five Forces Analysis5.8.1 Threat from New Entrants5.8.2 Threat from Substitutes5.8.3 Bargaining Power of Suppliers5.8.4 Bargaining Power of Buyers5.8.5 Intensity of Competition Rivalry5.9 Regulatory Landscape

6 Biosimilars Market, by Product6.1 Introduction6.2 Monoclonal Antibodies6.2.1 Infliximab6.2.1.1 Infliximab Accounted for the Largest Share of the Monoclonal Antibodies Market6.2.2 Trastuzumab6.2.2.1 Rising Incidence of Cancer to Drive Market Growth6.2.3 Rituximab6.2.3.1 Rising Incidence of Autoimmune Diseases and Cancer are Key Drivers for Market Growth6.2.4 Adalimumab6.2.4.1 Adalimumab to Register the Highest CAGR in the Monoclonal Antibodies Market6.2.5 Other Monoclonal Antibodies6.3 Insulin6.3.1 Increasing Incidence of Diabetes to Support Market Growth6.4 Granulocyte Colony-Stimulating Factor6.4.1 G-Csf is Used to Treat Cancer Patients with Neutropenia Occurring After Chemotherapy6.5 Erythropoietin6.5.1 Rising Incidence of Blood Disorders Will Drive Market Growth6.6 Recombinant Human Growth Hormone6.6.1 Market Growth is Driven Primarily by the Increasing Incidence of Growth Deficiency Disorders6.7 Etanercept6.7.1 APAC to Witness the Highest Growth in the Etanercept Market During the Forecast Period6.8 Follitropin6.8.1 Increasing Application of Follitropin in Infertility Treatment to Drive Market Growth6.9 Teriparatide6.9.1 Increasing Incidence of Osteoporosis is the Major Factor Driving Market Growth6.10 Interferons6.10.1 Rising Incidence of Infectious Diseases to Support Market Growth6.11 Enoxaparin Sodium6.11.1 Wide Range of Applications Have Supported the Demand for Enoxaparin Sodium Biosimilars6.12 Glucagon6.12.1 Sandoz is a Major Player in the Glucagon Biosimilars Market6.13 Calcitonin6.13.1 Increasing Incidence of Osteoporosis to Drive Market Growth

7 Biosimilars Market, by Indication7.1 Introduction7.2 Oncology7.2.1 Rising Burden of Cancer to Drive the Demand for Biosimilars7.3 Inflammatory & Autoimmune Diseases7.3.1 Changes in Lifestyle and Environmental Conditions Have Increased the Incidence of Inflammatory & Autoimmune Diseases7.4 Chronic Diseases7.4.1 High Burden of Cvd & Diabetes Worldwide to Drive Market Growth7.5 Blood Disorders7.5.1 Increasing Incidence of Blood Disorders Has Increased the Demand for Biosimilars for this Indication Segment7.6 Growth Hormone Deficiency7.6.1 Growing Use of Biosimilars for the Treatment of this Medical Condition to Support Market Growth7.7 Infectious Diseases7.7.1 Biosimilars Market for Infectious Diseases is Expected to be the Highest in the Asia-Pacific7.8 Other Indications

8 Biosimilars Market, by Region

9 Competitive Landscape9.1 Introduction9.2 Right-To-Win Approach9.3 Revenue Share Analysis of Key Market Players9.4 Market Share Analysis9.5 Company Evaluation Quadrant9.5.1 Stars9.5.2 Emerging Leaders9.5.3 Pervasive Players9.5.4 Participants9.6 Company Evaluation Quadrant: Start-Ups/Smes9.6.1 Progressive Companies9.6.2 Starting Blocks9.6.3 Responsive Companies9.6.4 Dynamic Companies9.7 Competitive Benchmarking9.7.1 Company Product Footprint9.7.2 Company Indication Footprint9.7.3 Company Regional Footprint9.8 Growth Strategies Adopted by Emerging and Key Players9.8.1 Product Launches & Approvals9.8.2 Deals9.8.3 Other Developments

10 Company Profiles10.1 Major Players10.1.1 Novartis Ag10.1.2 Pfizer Inc.10.1.3 Dr. Reddy's Laboratories Ltd.10.1.4 Amgen Inc.10.1.5 Eli Lilly and Company10.1.6 Teva Pharmaceutical Industries Ltd.10.1.7 Fresenius Se & Co. KGaA10.1.8 Stada Arzneimittel Ag10.1.9 Boehringer Ingelheim10.1.10 Gedeon Richter plc10.1.11 Celltrion10.1.12 Samsung Biologics10.1.13 Coherus Biosciences10.1.14 Biocon Limited10.1.15 Viatris10.2 Other Players10.2.1 Amega Biotech10.2.2 Apotex Inc.10.2.3 Biocad10.2.4 Mabxience10.2.5 Probiomed S.A. De C.V.10.2.6 Fujifilm Kyowa Kirin Biologics Co., Ltd.10.2.7 Intas Pharmaceuticals Ltd.10.2.8 Theramex10.2.9 Reliance Life Sciences10.2.10 Kashiv Biosciences

11 Appendix

For more information about this report visit https://www.researchandmarkets.com/r/mrja2j

Media Contact:

Research and Markets Laura Wood, Senior Manager [emailprotected]

For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets

http://www.researchandmarkets.com

Go here to see the original:

Biosimilars Market by Product, Indication and Region - Global Forecast to 2026 - PRNewswire